




Sepsis, and related complications, is still a common cause of death in
hospitalized patients worldwide, especially in critically ill neonates and
children. Sepsis is also responsible for significant morbidity, and
financial burden. It is very important to recognize sepsis early, since
delayed diagnosis is associated with worse outcome. The early detection
of sepsis remains a great challenge for clinicians because the use of blood
cultures, the gold standard for diagnosis of bacteremia, is fraught with
difficulties. The role of different immune and metabolic biomarkers is to
improve the diagnosis, treatment and prognosis of sepsis. White blood
cell count, C-reactive protein and procalcitonin are currently the most
widely used biomarkers, but they have limited abilities to
distinguish sepsis from other inflammatory conditions or to predict
outcome. In this review, these biomarkers will be discussed along with
novel diagnostic, prognostic and treatment response biomarkers,
including interleukins -6, -8, -18, tumor necrosis factor – alpha, CD11b,
CD64 and CD15s. The future of sepsis biomarkers lies in extensive
validation studies of all novel biomarkers and their combinations as early
predictors of sepsis. Also, research to identify novel sepsis biomarkers
and develop specific therapeutic strategies based on biomarker
information has to be continued.
Key words: infant, child, biomarkers, CD15s antigen, C-reactive
protein, procalcitonin
Introduction
Serious bacterial infections (SBI) are among the leading causes of
morbidity and mortality in children worldwide, with a reported rate in
young febrile infants between 8.5% and 12%. (1-3) Sepsis, a diagnosis
established according to criteria defined by Levy et al. (4), including
documented or suspected infection and findings of inflammation such as
hemodynamic instability, tissue perfusion alteration and indications of
organ dysfunction, is a leading cause of death in critically ill patients
despite the use of broad spectrum antibiotics and modern resuscitation
therapies. (5) Besides sepsis, the SBI group includes microbiologically
confirmed bacteraemia, bacterial meningitis, urinary tract infection,
pneumonia confirmed by an infiltrate on chest x ray, bacterial
gastroenteritis, or cellulitis. (6) Early recognition of SBI is associated with
better treatment outcome. (7) Unfortunately, diagnosis of bacterial
infections is sometimes challenging, because the use of blood culture, the
gold standard for diagnosis of bacteremia, is fraught with difficulties.
First, incubation of bacteria may take several days (2-4 days). Second,
genuine bacteremia may remain undetected in a large proportion of
infected cases because of the small volume of blood taken. Third,
bacteremia in the neonate may often be transient or intermittent,
especially during the early stages of infection. (8) All of this has led to the
investigation of various other biomarkers.
Biomarkers are extremely important in the process of diagnosis of sepsis
and evaluation of its severity because they can indicate the presence or
absence or severity of sepsis, (9) and can help differentiate bacterial from
viral and/or fungal infection. It remains difficult to differentiate sepsis
from other noninfectious causes of systemic inflammatory response
syndrome, and there is continuous search for better biomarkers of sepsis.
Based on the National Institutes of Health consensus conference in 2001,
(10) a biomarker is defined as a characteristic that can be measured
objectively and evaluated as an indicator of normal biological processes,
pathologic processes, or pharmacologic responses to a therapeutic
intervention. There are four major types of biomarkers: diagnostic,
monitoring, stratification and surrogate biomarkers. (9,11) Diagnostic
biomarkers serve to identify the presence or absence of a disease or other
clinical condition. The majority of diagnostic biomarkers are of most
value within a specific clinical context since it is very rare that a
diagnostic biomarker is strictly present or absent. The presence of a
biomarker is measured and cut-offs are defined to establish the presence
or absence of disease. This class includes the subset of screening
biomarkers. Monitoring biomarkers are molecules or proteins whose
levels change dynamically as a disease process evolves or in response to
applied therapeutic interventions. Valuable monitoring biomarkers must,
therefore, be functionally or biologically linked to the mechanism of
action of a given therapeutic intervention. Stratification biomarkers are
useful to sort a population of patients into different classes of severity. An
effective and useful stratification biomarker can identify higher risk
patients who would benefit from more toxic, more aggressive, or higher
risk therapies. Finally, surrogate biomarkers are used to predict outcome
of a disease process rather than follow its course or to titrate therapy.
They serve as proxy end points for severe or rare patient-centered
outcomes such as death or significant complications.
In order to be clinically useful, a biomarker should have a well-defined
cut-off value to differentiate infected from non infected patients, and it
should be able to do that at an early stage of disease. For diagnostic
purposes, a very high sensitivity and negative predictive value
(approaching 100%) and good specificity and positive predictive value
(>85%) are desirable. (8) However, if the diagnostic marker is unable to
satisfy the above criteria, then the optimal cut-off could be chosen so that
both the sensitivity and the specificity approach 80%. Second, the
kinetics of a biomarker should be considered because a rapid increase of
its value would allow a good discrimination between health and disease.
Third, with reference to the laboratory characteristics, the infection
biomarker should be biochemically stable because it might be necessary
to keep blood samples stored.
A set of different tests including the white blood cell (WBC) count,
leukocyte differential counting for evidence of a myeloid left shift,
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
procalcitonin (PCT), and microbiologic cultures is used in the laboratory
evaluation of patients with suspected infection or sepsis. Also, many
different clinical scores have been developed to detect patients at high or
low risk of sepsis or other SBI. However, none of the evaluated clinical
scales and laboratory markers have been shown to be sensitive or specific
enough to be used as a tool to determine the absence or presence of SBI
in neonates and children with absolutely no doubt. Therefore, the new
generation of biomarkers and improved diagnostics for infection have
been directed towards soluble biomarkers in the serum or plasma, and
towards analysis of leukocyte cell surface molecules. (12,13)
White blood cells (WBC) count is the most commonly used
biomarker in clinical practice and diagnostic algorithms commonly used
to evaluate neonates, infants or children with fever include the
interpretation of WBC. Among febrile children a WBC of < 5 or ≥ 15 x
109/l is considered to be associated with an increased risk of SBI.
However, some studies have indicated that WBC is not a reliable nor
accurate indicator of SBI in febrile infants. In 2001, Galletto-Lacour et al.
(14) confirmed that total and differential leukocyte count performed
poorly compared to PCT and CRP. WBC cut-off of 15 x 109/l had a
sensitivity of 68% and specificity of 77%. Band count > 1.5 x 109/l
sensitivity was 29%, and specificity 91%. (14) Bonsu et al. (15) found that
use of the WBC cut-off of 15 x 109/l would have yielded a sensitivity of
only 45% and specificity of 78%. Even the use of a lower cut-off of 5 x
109/l would not detect 21% patients with bacteremia. Similar results were
presented by the study done by Galletto-Lacour in 2003. (16) They
showed that WBC cut-off of 15 x 109/l had a poor sensitivity of 52% and
specificity of 74%. The value of band count was even worse and extremely
poor, with sensitivity of only 11% (16). Rudinsky et al. (17) also found that
the suggested cut-offs of a WBC count < 5 x 109/l and > 15 x 109/l were
not accurate and reliable predictor of SBI in infants age 3 to 24 months
since no statistical difference was detected in the WBC count between the
SBI and non-SBI groups.
C reactive protein (CRP) is an acute-phase reactant synthesized by
the liver in response to elevated levels of the proinflammatory cytokines
(IL-1, IL-6 and TNF-α). It is produced within 4–6 hours after onset of
tissue injury or inflammation, and it doubles every 8 hours before
peaking around 36 hours. (18) CRP is frequently used as part of the
assessment of children with fever of unknown origin, however, its levels
become elevated in any disease process with tissue injury, not just
infection. CRP is also among the most widely used biomarkers in
neonates. (19) Franz et al. considered a CRP value >10 mg/L, in the
presence of one (or more) clinical sign(s) compatible with infection, as a
criterion to make a diagnosis of clinical septicemia in neonates. (20)
However, due to the time lag in the response of CRP to infection, some
clinicians use it in combination with other biomarkers. Pulliam et al. (21)
reported the results of a prospective study in 2001 examining the utility
of CRP in evaluating febrile children. Seventy-seven children 1 to 36
months of age were enrolled in this study. CRP was found to be a much
more useful biomarker than WBC count for this group of patients, with
sensitivity of 79% and specificity of 91%. Galetto-Lacour et al. (14) also
evaluated the utility of CRP as a potential biomarker of infection.
Children were prospectively enrolled at a pediatric emergency
department in a European university hospital. A CRP cutoff of 40 mg/l
resulted in a sensitivity of 89% and specificity of 75%; more sensitive
than Pulliam et al., (21) but also less specific. Similar results were found
by Galetto-Lacour two years later in a follow-up study, (16) which showed
that CRP levels were superior to WBC counts in detecting SBIs, with
reported sensitivity and specificity of 79%. The study by Olaciregui et al.,
(6) focused on infants aged ≤3 months, also showed that CRP appears to
be useful in predicting SBI and recommended that it should be used in
combination with other markers for management of febrile patients in
this age group. Other authors, (3) studying the same age group, similarly
reported that various cut-offs of CRP had a better sensitivity and
specificity than WBC cut-offs. Nevertheless, despite the high specificity of
CRP, its sensitivity was low.
Procalcitonin (PCT) is a 116-aminoacid peptide and also an acute-
phase reactant. PCT level begins to rise 4 hours after exposure to
bacterial endotoxin, peaks at 6-8 hours, and remains elevated for at least
24 hours. (22) It has been used to diagnose the severity of systemic
inflammatory response, to determine the progression of infection to
sepsis and septic shock, to assess responsiveness to treatment, and to
estimate prognosis. (22) Increases in PCT occur before, and more rapidly,
than increases in CRP and its peak level is achieved sooner. Additionally,
when the patient responds appropriately to therapy, PCT levels decrease
to normal much quicker than those of CRP. The most important clinical
applicability of PCT as a biomarker may be in determining the initiation
(diagnostic biomarker) and duration (monitoring biomarker) of
antibiotic therapy. (11) All studies on severe, invasive bacterial infections
in children report higher sensitivities and specificities of PCT than for
CRP, (23-25) although its value has also been challenged. (22) In 2003,
Galetto-Lacour et al. (16) published the results of their prospective
research confirming the superiority of PCT. One hundred and ten febrile
children aged 7 days to 36 months presenting to a pediatric emergency
department were enrolled. A PCT cutoff of 0.5 ng/ml resulted in a
sensitivity of 93% and specificity of 74%, similar to the author’s previous
findings. CRP was less sensitive and specific: the proposed optimum
cutoff of 40 mg/L was 52% sensitive and 74% specific. The large study on
PCT was that of Gendrel et al. (26) The authors, in a group of children
hospitalized after admission to the Emergency Department, found that
PCT, at the cut-off of 2 ng/mL, had a very high sensitivity (96%) and
specificity (87%) in detecting invasive bacterial infection and performed
much better than CRP at different cut-offs. Similar results were reported
by Fernandez Lopez et al. (23) Four hundred and forty-five children were
enrolled. Eighty children were diagnosed with “localized” bacterial
infections while 150 patients were diagnosed with “invasive” bacterial
infections (sepsis, pyelonephritis, meningitis, and lobar pneumonia). The
authors found PCT to be the best predictor of bacterial infection. Using a
calculated optimum cut-off of 0.53 ng/ml, the authors reported
sensitivity of 65.5%, and specificity of 94.3%. CRP (> 27.5 mg/L) was less
sensitive (63.5%) and less specific (84.2%). When used to differentiate
only those children who were diagnosed with invasive bacterial disease,
PCT ≥ 0.59 ng/ml had a sensitivity of 91.3% and specificity of 93.5%,
much better than the 78% and 75% noted with CRP, respectively. In this
study, both PCT and CRP were found to perform better when compared
to WBC and ANC in detecting invasive infections.
Cytokines
Sepsis is a syndrome characterized by a systemic inflammatory response
in which the cytokines produced by immune cells, in response to bacterial
products, are important mediators. Increased plasma levels of cytokines,
such as tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 and
IL-6 have been found in sepsis, and a significant correlation between high
levels of these cytokines and poor clinical outcome has been reported.
(27,28) The initial cytokinaemia is accompanied by a compensatory
response of raised concentrations of circulating anti-inflammatory
cytokines (eg, interleukin 10)
Interleukin 6 (IL­6) is an interesting biomarker for clinicians since its
levels appear to rise several hours prior to elevation of CRP in the face of
infection, and it was found more useful than IL-1 or TNF-alpha in
predicting bacteremia in children. (29) Plasma levels of IL-6 were
significantly higher in newborns with proven sepsis and clinical sepsis
compared to a control group of newborns. (30) These results showed that
IL-6 plasma levels have a high diagnostic specificity for neonatal sepsis
(92%), however with a lower sensitivity of 47%. (30) Galetto-Lacour et al.
(14) also found that levels of IL-6 were significantly higher in the group of
children with SBI compared to the benign infection group. Gendrel et al.
(26) measured IL-6 levels in febrile children. In their study, IL-6 was
lower in patients with viral infections. Surprisingly, some of the highest
levels of IL-6 were also found in children with viral infections. In the
same study, it was found that for the group with SBI, the calculated area
under the curve (AUC) for IL-6 was only 0.78, compared with 0.94 for
PCT and 0.78 for CRP. Therefore, the authors noted that IL-6 was the
least useful marker. (26) A similar conclusion was reported by Lacour et
al. (14) who examined the usefulness of IL-6 in predicting SBI in febrile
children during their 2001 study of CRP. They also found that
interleukins were not as useful as PCT or CRP, with lower sensitivities
and specificities.
Interleukin­8 (IL­8) is a potent neutrophil activating agent whose
elevated levels predict organ failure in adults with septic shock, (31) and
serve as a valuable biomarker of neonatal sepsis. (27,32) It was found
that IL-8 is superior to CRP in detection of neonatal sepsis (32) and that
elevated levels of IL-8 can serve as a promising marker of early-onset
neonatal sepsis. (33) However, Galetto-Lacour et al. (14) challenged these
results and reported that the levels of IL-8 were comparable between the
group of children with SBI and the benign infection group.
Interleukin­18 (IL­18) is a proinflammatory cytokine produced by
activated macrophages that participates in the induction of cell-mediated
immunity. IL-18 is also among biomarkers which are gaining more
attention recently as a potential predictor of sepsis, but the overall data
are currently not as extensive as that for PCT. (11) Increased IL-18 levels
are found in many inflammatory conditions, including neonatal
infections, and sepsis. (34) Kingsmore et al. reported that IL-18 and
seven other serum biomarkers were elevated in preterm infants who
developed symptoms of infection. (35) However, Bender et al.
determined in their population of neonates that IL-18 had no diagnostic
ability. (36) Therefore, the utility of IL-18 as a diagnostic biomarker for
sepsis remains to be further evaluated, and much more study, especially
in the pediatric population, is needed to clarify the utility of this
biomarker in the diagnosis of sepsis.
Tumor necrosis factor­alpha (TNF­alpha) is another biomarker
whose plasma levels were found significantly increased in the group of
neonates with proven sepsis compared to the control group of patients. In
that study, the sensitivity and specificity of TNF-alpha for the diagnosis
of neonatal sepsis were 60% and 84%, respectively. (30) TNF-alpha is
also a sensitive marker and has a high sensitivity and negative predictive
value for detecting late onset infection in very low birth weight (VLBW)
newborns. (37) In contrast, IL­1β and E­selectin had rather low
sensitivity for detecting late onset infection within the first 48 hours in
VLBW. In the same article it was shown that the use of multiple markers
(IL-6, TNF-alpha and CRP) in combination, was associated with higher
sensitivity and better negative predictive values. In particular, the use of
CRP with either IL-6 or TNF-alpha seemed to be most sensitive for
confirming infection. After calculating all possible combinations and
permutations for these three tests within the first 48 hours of infection,
CRP and IL-6 on day 0 combined with either TNF-alpha on day 1 or CRP
on day 2 provided the best overall sensitivity (98%) and specificity (91%)
for the diagnosis of late onset infection. (37)
Leukocyte cell surface molecules
Leukocyte cell surface molecules mediate many of the interactions
between the immune system and antigens. The relatively new approach
to rapid and early diagnosis of infection or sepsis is to utilize some of the
molecular changes of the innate immune response to detect the presence
of infection or sepsis. Neutrophils exist in three states: resting
(unstimulated), primed (encounter with an inflammatory or microbial-
derived product that has lowered the threshold stimulus needed for
activation), and activated (undertaking a defined function). Bacterial
elimination is dependent on the rapid recruitment of blood neutrophils
into sites of infection. Therefore, the effective movement of leukocytes
from within the vasculature to the extravascular space is an extremely
important physiological process. This process occurs through a cascade of
events typically described as attachment (initial tethering), rolling, firm
adhesion, and extravasation. Binding of neutrophils to the vascular
endothelium is controlled by the sequential activities of two families of
adhesion molecules; the selectins and integrins. The selectins promote
the initial rolling or tethering of the neutrophils to the endothelium
under the force of blood flow, whereas the integrins induce firm
adhesion. (38) There are two subfamilies of integrins (β1 and β2). The β2
integrins have a common β-subunit (β2, CD18) and distinct α-subunits
(CD11a, CD11b, CD11c, and CD11d). On the neutrophil surface, L-selectin
(CD62L) interacts with specific oligosaccharide moieties on endothelial-
cell surface glycoproteins, whereas on the endothelium, E-selectin
(CD62E) and P-selectin (CD62P) similarly recognize specific neutrophil
carbohydrate motifs. Transient rolling helps neutrophils to make contact
with inflammatory factors that are expressed on the endothelial surface.
This interaction stimulates the neutrophils to rapidly increase the avidity
of the β2 integrins for the endothelial ligand. The integrin CD11b/CD18
(complement receptor type 3 [CR3], Mac-1, or αMβ2) is the predominant
β2 integrin in neutrophils. In resting non-stimulated neutrophils from
adults, 95% of the total cell content of CD11b/CD18 complexes occurs as
membrane components of specific granules and secretory vesicles, i.e., in
intracellular storage granules, with only 5% of the complexes expressed
on the cell surface. (39)
The expression of CD11b on neutrophils in sepsis has been reported to
be increased and serves as an activation marker of neutrophils, may
predict the development of organ failure in patients with septic shock
(31) and is indicative of a poor prognosis. (40) The Turunen et al. study
shows that determination of CD11b expression may be useful in early
identification of ELBW infants with late-onset sepsis. (41) The results of
this study demonstrated that CD11b expression has increased in some
infants from the infection group up to 3 days before the onset of
symptoms suggesting that CD11b measurements may enable, at least in
some infants, early diagnosis of infection. It has been also found that an
increase in neutrophil surface density of CD11b/CD18 is a promising and
a highly effective sepsis marker for diagnosing early-onset infection in
term neonates as well. (33,42) The results of those studies show, on the
first day of life, a two- to fourfold increase in neutrophil CD11b
expression in infants with blood-culture positive sepsis. This increase is
similar to that demonstrated in neutrophils from adults with blood-
culture positive sepsis. (31) Similarly, in 2012, Genel et al. (43) reported
that neutrophil and monocyte CD11b expressions were significantly
elevated in infected neonates as compared with the control group of
subjects. They also reported that neutrophil CD11b had a sensitivity of
66% and specificity of 71% for detecting neonatal infection, while
monocyte CD11b had a sensitivity of 70% and specificity of 62% for
detecting neonatal infection. (43) However, decreased values of the
CD11b expression on neutrophils in sepsis were also found. (44)
During rolling, the adhesive contact zone between the cell and the vessel
is rapidly translated along the vessel wall. This requires the rapid
breakage and formation of adhesive bonds. As mentioned earlier, only
certain adhesion molecules, including selectins and some integrins, have
been found to support rolling. Chen et al. (45) have identified antibodies,
all of the IgM class, to carbohydrate antigens CD15 and CD15s. Lewis x
(CD15) and sialyl­Lewis x (CD15s) are expressed on circulating
neutrophils and monocytes and, upon recognition by endothelial
selectins, mediate leukocyte endothelium interactions and mediate
tethering and rolling by serving as the ligands for E and P-selectin. CD15
has an intracellular pool in the membranes of the primary and secondary
granules, and surface expression is increased upon stimulation with
chemotactic peptides. Zen et al., in 2007, have shown that both CD11b
and CD18 subunits of Mac-1 purified from normal human neutrophils are
decorated with sLex or sLex related moieties that mediate the binding of
β2 integrin with E-selectin. (46) The ligation of sLex moieties by specific
anti-sLex antibody significantly affects neutrophil functions including
induction of neutrophil aggregation, induction of secondary granule
release and impairment of neutrophil transmigration. The authors also
observed that N-formyl-methionine-leucine-phenylalanine (fMLP)
stimulation strongly enhanced the neutrophil cell surface expression of
sLex moieties and the up-regulation pattern was similar to that of Mac-1
with fMLP stimulation. (46) So far, only one research evaluated the
CD15s as predictor of SBI and its role in differentiation between bacterial
and viral infection. (47) It was found that the percentage of CD15s+
neutrophils (%CD15s+) and absolute count of CD15s+ neutrophils (AC-
CD15s+) were significantly different between the groups and both of
them proved to be valuable biomarkers for differentiation between
bacterial and viral infection.
The surface receptors of neutrophils recognize bacterial antigens and this
interaction activates the neutrophils to phagocyte. Neutrophil binding of
bacteria is greatly augmented when the pathogens are coated with IgG.
Fcγ receptor I (FcγRI), which is the high affinity receptor for monomeric
IgG1 and IgG3, is recognized by the monoclonal antibody CD64. (48) It
has a molecular weight of 72 kDa and it encoded by three genes on the
long arm of chromosome 1. CD64 is expressed only to a very low extent
on resting neutrophils, (12) and is considered to be a marker of activated
neutrophils. The quantification of CD64 expression on the surface of
neutrophils by flow cytometry has been proposed as a diagnostic test for
sepsis in neonates, (30,49,50) and hospitalized children. (51,52) In
neonatology, CD64 has been used to identify premature and term
neonates with sepsis. In most of these studies, CD64 has appeared to
perform moderately well, often in combination with other markers or
hematologic parameters. Ng et al. showed that CD64 levels had high
sensitivity (95–97%) and negative predictive value (97–99%) for early-
and late-onset infection in infants of very low birth weight. (37,49) Using
the additional biomarkers like IL-6 or CRP, the sensitivity was increased
to 100% and the specificity exceeding 88% was noticed. (37) Layseca-
Espinosa et al. also found that expression of CD64 is a highly specific
laboratory indicator of neonatal sepsis (96.8%), although with a low
sensitivity (25.8%). (30) Their data indicate that the high specificity of
elevated levels of CD64 for neonatal sepsis is achieved through a single
determination and the high percentage of CD64+ cells seen in neonatal
sepsis is maintained in these patients for at least 24 h. A large cohort
study also demonstrated that neutrophil CD64 was substantially up-
regulated and useful (sensitivity 96% and specificity 81%) for identifying
neonates with early-onset clinical sepsis and pneumonia. (49) The
authors reported that additional use of CRP did not significantly improve
the sensitivity of neutrophil CD64, but adversely affected the specificity
of the test. In critically ill neonates and children, it was found that
diagnostic accuracy of CD64 index was higher than the diagnostic
accuracy of routine laboratory markers PCT and CRP at the time of
suspected sepsis and 24 h later. (51) A similar conclusion was reported by
Davis et al. (53) In their research, CD64 had high diagnostic performance
as a predictor of sepsis (sensitivity 87.9%, specificity 71.2%), and was
found to be a better diagnostic biomarker of infection/sepsis when
compared with CRP, band counts, and absolute neutrophil counts. (53)
Cid et al. (54) recently conducted a meta-analysis of the literature on
CD64 and calculated mean pooled results for various performance
characteristics. Overall, for adult and pediatric patients, pooled
sensitivity was 79% and specificity 91% for neutrophil CD64 expression
as marker of bacterial infection. For the pediatric studies, they found a
mean sensitivity of 71% and a mean specificity of 87% for CD64. (54)
Other biomarkers
A number of acute phase proteins including alpha1-antitrypsin,
fibronectin, haptoglobin, lactoferrin, neopterin, inter-a inhibitor
proteins, granulocyte colony stimulating factor, orosomucoid, and
antithrombin have been evaluated in relation to neonatal sepsis.
Although these acute phase proteins may be candidate biomarkers for
sepsis, none has been routinely used clinically or studied on a large scale.
Serum amyloid A (SAA) is an acute phase protein induced by the
proinflammatory cytokines. There is a significant increase in SAA levels
from 8 to 24 h after the onset of sepsis and it was shown that SAA had
better diagnostic accuracy than CRP at septic evaluation in neonatal early
onset sepsis. (55) Interleukin­12 was measured in newborns at the time
when sepsis was first suspected clinically and was higher in patients with
sepsis than in those without. (56) Interferon­induced protein 10
(IP­10) was higher in neonates with sepsis and necrotizing enterocolitis
than in neonates who had only necrotizing enterocolitis. (57)
Lipopolysaccharide­binding protein (LBP), a 50-kDa acute-phase
protein, is mainly synthesized in the liver. It binds with high affinity to
lipopolysaccharide (LPS) in the plasma, transfers LPS to membrane
bound or soluble CD14, and modulates the microbial-induced activation
of the inflammatory host response. It was reported that LBP has better
sensitivity and specificity for detecting sepsis than LPS-soluble, CD14
complexes, and PCT in early onset sepsis, but is equally effective as CRP
in detecting sepsis in neonates older than 48 h. (58)
Conclusion
In conclusion, it is evident that, to date, none of the above mentioned
biomarkers alone or in combination are 100% sensitive and specific,
allowing neonatologists or pediatricians to withhold antibiotic treatment
in an infant or older child with clinical signs suggestive of infection.
Furthermore, analysis of some biomarkers in the clinical setting, like cell
surface markers, requires specialized equipment and qualified personnel
readily available. This limits the practical application of this technology.
Therefore, the search for better biomarkers continues…
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